Graham J. Mann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Graham J. Mann has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Richard Scolyer
Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
120 shared publications - Georgina V. Long
Melanoma Institute Australia, Sydney
78 shared publications - Nicholas K. Hayward
Cancer Research Program, QIMR Berghofer, Brisbane, Australia
76 shared publications - James S. Wilmott
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
68 shared publications - John F. Thompson
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
54 shared publications - Richard F. Kefford
Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia
49 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
Purpose:Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone.Experimental Design:Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death.Results:When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis.Conclusions:Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
Purpose:Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone.Experimental Design:Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death.Results:When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis.Conclusions:Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
- 20 October 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5225-5236
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
- 20 October 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5225-5236
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Per class AUROC using ProCan Compendium and external datasets
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Per class AUROC using ProCan Compendium and external datasets
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
ProCanFDL with external datasets
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
ProCanFDL with external datasets
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Sample sizes of Sites 1-4 across ten experiments
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Sample sizes of Sites 1-4 across ten experiments
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Protein overlap between global and local models based on SHAP rankings
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Protein overlap between global and local models based on SHAP rankings
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Effects of adding external datasets
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
Effects of adding external datasets